Voydeya approved in the EU as add-on treatment to ravulizumab
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
ALPHA Phase III trial showed first-in-class, oral, Factor D inhibitor as add-on to Ultomiris or Soliris improved haemoglobin levels and reduced anaemia and fatigue
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
10th edition of the event is scheduled to be held during May 30-June 1 at Hitex, Hyderabad
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Subscribe To Our Newsletter & Stay Updated